A Phase II, Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled, Parallel- Groups Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Treatment of Subjects With Intermittent Claudication (IC)

Trial Profile

A Phase II, Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled, Parallel- Groups Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Treatment of Subjects With Intermittent Claudication (IC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs PLX PAD (Primary)
  • Indications Intermittent claudication; Peripheral arterial disorders
  • Focus Therapeutic Use
  • Sponsors Pluristem Therapeutics
  • Most Recent Events

    • 18 Jan 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Apr 2018.
    • 12 Jan 2017 According to a Pluristem Therapeutics media release, the company expect to report top line results of this study in early 2018
    • 12 Jan 2017 According to a Pluristem Therapeutics media release, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top